Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SHP465 12.5 mg | Experimental | Subjects will receive SHP465 12.5 mg |
|
| SHP465 37.5 mg | Experimental | Subjects will receive SHP465 titrated up to 37.5 mg |
|
| Placebo | Placebo Comparator | Subjects will receive matching placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SHP465 12.5mg capsules (one capsule daily) | Drug | one capsule daily |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Adult Attention-deficit/Hyperactivity Disorder Rating Scale-4 (ADHD-RS) With Prompts Total Score at Visit 6 (Week 4) | The ADHD-RS was developed to measure the behaviors of children with Attention deficit hyperactivity disorder (ADHD). The adult ADHD-RS with prompts consists of 18 items designated to reflect current symptomatology of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), with the total score for the rating scale ranging from 0 to 54. Higher score = more severe symptoms.The scale is subdivided into 2 subscales of 9 symptoms each: hyperactivity/impulsivity and inattentiveness. Adult prompts are included with the ADHD-RS to create a semistructured measurement that allows the clinician to probe the extent, frequency, breadth, severity, and consequences of these symptoms to ascertain impairment in an adult population. | Baseline, Visit 6 (Week 4) |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Global Impression of Improvement (CGI-I) Score at Visit 6 (Week 4) | CGI scales permit a global evaluation of the participant's severity and improvement over time. CGI-I was performed to rate the severity of a participant's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). | Visit 6 (Week 4) |
Not provided
Inclusion Criteria:
Subject must be 18-55 years of age
Subject is able to provide written, personally signed and dated informed consent.
Subject is willing and able to comply with all of the testing and requirements defined in the protocol
Subject, who is a female, must not be pregnant.
Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities.
Subject has a primary diagnosis of ADHD.
Subject has an adult ADHD-RS with prompts total score ≥28 at the baseline visit.
Subject must have a minimum level of intellectual functioning, as determined by the investigator.
Subject is able to swallow a capsule.
Subject is currently not on ADHD therapy or is not completely satisfied with any aspect of their current ADHD therapy.
Exclusion Criteria:
Subject has a current, comorbid psychiatric diagnosis with significant symptoms.
Subject is considered a suicide risk in the opinion of the investigator
Subject has a body mass index (BMI) of <18.5 kg/m2 at the screening visit.
Subject has a BMI ≥40 kg/m2 at the screening visit.
Subject has a concurrent chronic or acute illness, disability, or other condition.
Subject has a history of seizure, a chronic or current tic disorder, or a current diagnosis of Tourette's disorder.
Subject has a history of moderate to severe hypertension.
Subject has a known history of symptomatic cardiovascular disease
Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
Subject has any clinically significant ECG or clinically significant laboratory abnormality at the screening visit.
Subject has current abnormal thyroid function
Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
Subject has failed to respond, to an adequate course(s) of amphetamine therapy.
Subject has a history of suspected substance abuse or dependence disorder.
Subject has a positive urine drug result at the screening visit (with the exception of subject's current stimulant therapy, if any) or Subject has taken another investigational product or has taken part in a clinical study within 30 days prior to the screening visit.
Subject has previously completed, has discontinued, or was withdrawn from this study.
Subject is taking any medication that is excluded or has not been appropriately washed out according to the protocol requirements.
Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance.
Subject is female and is pregnant or lactating.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pharmacology Research Institute | Encino | California | 91316 | United States | ||
| Pharmacology Research Institute (Pri) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28712074 | Derived | Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study. CNS Drugs. 2017 Aug;31(8):685-697. doi: 10.1007/s40263-017-0455-7. |
Not provided
Not provided
A total of 369 participants were screened and 275 participants were enrolled in the study.
The study was conducted at 43 study centers in the United States between 19 November 2015 and 24 March 2016.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Participants received placebo matched to SHP465 capsule orally once daily for 4 weeks. |
| FG001 | SHP465 12.5 mg | Participants received SHP465 capsule 12.5 milligram (mg) orally once daily for 4 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Other |
Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily) |
|
| SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily) | Drug | One capsule daily |
|
| Los Alamitos |
| California |
| 90720 |
| United States |
| Pharmacology Research Institute (Pri) | Newport Beach | California | 92660 | United States |
| Nrc Research Institute | Orange | California | 92868 | United States |
| Elite Clinical Trials | Wildomar | California | 92595 | United States |
| McB Clinical Research | Colorado Springs | Colorado | 80910 | United States |
| Florida Clinical Research Center Llc | Bradenton | Florida | 32401 | United States |
| Gulfcoast Clinical Research Center | Fort Myers | Florida | 33912 | United States |
| Sarkis Clinical Trials | Gainesville | Florida | 32607 | United States |
| Clinical Neuroscience Solutions, Inc | Jacksonville | Florida | 32256 | United States |
| Florida Clinical Research Center, Llc | Maitland | Florida | 32751 | United States |
| Qps Mra, Llc | Miami | Florida | 33143 | United States |
| Medical Research Group of Central Florida | Orange City | Florida | 32763 | United States |
| Clinical Neuroscience Solutions, Inc | Orlando | Florida | 32801 | United States |
| Northwest Behavioral Research Center | Marietta | Georgia | 30060 | United States |
| Capstone Clinical | Libertyville | Illinois | 60048 | United States |
| Baber Research Group, Inc | Naperville | Illinois | 60563 | United States |
| Psychiatric Associates | Overland Park | Kansas | 66211 | United States |
| Louisiana Research Associates, Inc. | New Orleans | Louisiana | 70114 | United States |
| Rochester Center For Behavioral Medicine | Rochester Hills | Michigan | 48307 | United States |
| Clinical Neurophysiology Services | Sterling Heights | Michigan | 48314 | United States |
| Psychiatric Care and Research Center | O'Fallon | Missouri | 63368 | United States |
| Midwest Research Group | Saint Charles | Missouri | 63304 | United States |
| Premier Psychiatric Research Institutute | Lincoln | Nebraska | 68526 | United States |
| Center For Psychiatry and Behavioral Medicine, Inc | Las Vegas | Nevada | 89128 | United States |
| Princeton Medical Institute | Princeton | New Jersey | 08540 | United States |
| Bioscience Research Llc | Mount Kisco | New York | 10549 | United States |
| Nyu Langone Medical Center | New York | New York | 10016 | United States |
| Richard H Weisler, Md, Pa & Associates | Raleigh | North Carolina | 27609 | United States |
| Midwest Clinical Research Center | Dayton | Ohio | 45417 | United States |
| Ips Research Company | Oklahoma City | Oklahoma | 73103 | United States |
| Oregon Center For Clinical Investigations, Inc | Portland | Oregon | 97214 | United States |
| Oregon Center For Clinical Investigations | Salem | Oregon | 97301 | United States |
| Omega Medical Research | Warwick | Rhode Island | 02886 | United States |
| Rainbow Research, Inc. | Barnwell | South Carolina | 29812 | United States |
| Coastal Carolina Research | Mt. Pleasant | South Carolina | 29464 | United States |
| Clinical Neuroscience Solutions | Memphis | Tennessee | 38119 | United States |
| Futuresearch Trials of Dallas, Lp | Dallas | Texas | 75231 | United States |
| Bayou City Research, Ltd | Houston | Texas | 77007 | United States |
| Red Oak Psychiatry Associates | Houston | Texas | 77090 | United States |
| Houston Clinical Trials, Llc | Houston | Texas | 77098 | United States |
| Research Across America | Plano | Texas | 75093 | United States |
| Neuroscience, Inc | Herndon | Virginia | 20170 | United States |
| Eastside Therapeutic Resource | Kirkland | Washington | 98033 | United States |
| Summit Research Network (Seattle) Llc | Seattle | Washington | 98104 | United States |
| FG002 | SHP465 37.5 mg | Participants received SHP465 capsule of 12.5 mg during week 1 and 25 mg at week 2 followed by 37.5 mg at weeks 3 and 4 orally once daily. |
| TREATED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Safety set consisted of all participants in the randomized set (participants who signed informed consent for whom a randomization number had been assigned) who had taken at least 1 dose of investigational product.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Participants received placebo matched to SHP465 capsule orally once daily for 4 weeks. |
| BG001 | SHP465 12.5 mg | Participants received SHP465 capsule 12.5 mg orally once daily for 4 weeks. |
| BG002 | SHP465 37.5 mg | Participants received SHP465 capsule of 12.5 mg during week 1 and 25 mg at week 2 followed by 37.5 mg at weeks 3 and 4 orally once daily. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in the Adult Attention-deficit/Hyperactivity Disorder Rating Scale-4 (ADHD-RS) With Prompts Total Score at Visit 6 (Week 4) | The ADHD-RS was developed to measure the behaviors of children with Attention deficit hyperactivity disorder (ADHD). The adult ADHD-RS with prompts consists of 18 items designated to reflect current symptomatology of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), with the total score for the rating scale ranging from 0 to 54. Higher score = more severe symptoms.The scale is subdivided into 2 subscales of 9 symptoms each: hyperactivity/impulsivity and inattentiveness. Adult prompts are included with the ADHD-RS to create a semistructured measurement that allows the clinician to probe the extent, frequency, breadth, severity, and consequences of these symptoms to ascertain impairment in an adult population. | Full Analysis Set (FAS) consisted of all participants in the safety set who had at least 1 post dose baseline primary efficacy assessment (ADHD-RS with prompt total score) on treatment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline, Visit 6 (Week 4) |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Clinical Global Impression of Improvement (CGI-I) Score at Visit 6 (Week 4) | CGI scales permit a global evaluation of the participant's severity and improvement over time. CGI-I was performed to rate the severity of a participant's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). | Full-analysis set (FAS) consisted of all participants in the safety set who had at least 1 postdose baseline primary efficacy assessment (ADHD-RS with prompt total score) on treatment with number of participants evaluable for this outcome. | Posted | Mean | Standard Deviation | Units on a scale | Visit 6 (Week 4) |
|
From the Start of Study Drug Administration up to Follow-up (Week 5)
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Participants received placebo matched to SHP465 capsule orally once daily for 4 weeks. | 0 | 89 | 12 | 89 | ||
| EG001 | SHP465 12.5 mg | Participants received SHP465 capsule 12.5 milligram (mg) orally once daily for 4 weeks. | 0 | 92 | 44 | 92 | ||
| EG002 | SHP465 37.5 mg | Participants received SHP465 capsule of 12.5 mg during week 1 and 25 mg at week 2 followed by 37.5 mg at weeks 3 and 4 orally once daily. | 0 | 90 | 49 | 90 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dry mouth | Gastrointestinal disorders | MedDRA 18.1 | Non-systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 18.1 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 18.1 | Non-systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 18.1 | Non-systematic Assessment |
| |
| Bruxism | Psychiatric disorders | MedDRA 18.1 | Non-systematic Assessment |
| |
| Initial insomnia | Psychiatric disorders | MedDRA 18.1 | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA 18.1 | Non-systematic Assessment |
| |
| Irritability | Psychiatric disorders | MedDRA 18.1 | Non-systematic Assessment |
|
If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Shire | +1 866 842 5335 | ClinicalTransparency@shire.com |
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| Male |
|
| Change at Visit 6 |
|
|
| <0.001 |
| Difference of LS Mean |
| -13.4 |
| 2-Sided |
| 95 |
| -17.1 |
| -9.7 |
Between treatment groups of SHP465 37.5 mg and Placebo. |
| Superiority or Other (legacy) |
| Units | Counts |
|---|---|
| Participants |
|
|